Sold as Ophthaine, Ophthetic. Every FDA application for this active ingredient: 2 branded and 10 generic.
As of Nov 22, 2026, FDA lists 12 applications for Proparacaine hydrochloride (sold as Ophthaine, Ophthetic), first approved Jul 1, 1953, with 0 new uses approved and 0 published complete response letters.
| Jul 1, 1953 | OphthaineNDA 8883 ยท New molecular entity | Apothecon | 10 | Discontinued |
| Jan 23, 1961 | OphtheticNDA 12583 ยท New dosage form | Allergan | 29 | Discontinued |
| Dec 22, 1971 | AlcaineANDA 80027 | Alcon Laboratories | 24 | Marketed |
| Nov 1, 1974 | Proparacaine HydrochlorideANDA 84144 | Sola Barnes-Hind | 0 | Discontinued |
| Dec 19, 1974 | Proparacaine HydrochlorideANDA 84151 | Sola Barnes-Hind | 0 | Discontinued |
| Aug 5, 1982 | ParacaineANDA 87681 | Optopics | 1 | Discontinued |
| Jun 7, 1983 | KainairANDA 88087 | Pharmafair | 0 | Discontinued |
| Sep 29, 1995 | Proparacaine HydrochlorideANDA 40074 | Bausch & Lomb | 11 | Marketed |
| Mar 16, 2000 | Proparacaine HydrochlorideANDA 40277 | Rising Pharmaceuticals | 1 | Marketed |
| Aug 9, 2024 | Proparacaine HydrochlorideANDA 215816 | Somerset Therapeutics | 0 | Marketed |
| May 21, 2025 | Proparacaine HydrochlorideANDA 219136 | Mankind Pharma | 0 | Marketed |
| Oct 20, 2025 | Proparacaine HydrochlorideANDA 219294 | Micro Labs | 0 | Marketed |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Proparacaine HCl | Part D | $29K | โ6% | 913 |
| Comparison Between Outcomes of Closure of Idiopathic Macular Hole Using Autologus Tenon Capsule Graft and Internal Limiting Membrane Flap Techniques (Pilot Study)Macular Hole Surgery, ILM Peeling ยท Ain Shams University | Not applicable | Recruiting | Jun 8, 2026 |
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsDiabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) ยท Harrow Inc | Phase 4 | Enrolling by invitation | Mar 9, 2026 |
| Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?Epiphora, Dacryostenosis ยท Louisiana State University Health Sciences Center in New Orleans | Phase 4 | Recruiting | Dec 23, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA